HK1254397A1 - 通过t细胞疗法治疗cmv视网膜炎的方法 - Google Patents

通过t细胞疗法治疗cmv视网膜炎的方法 Download PDF

Info

Publication number
HK1254397A1
HK1254397A1 HK18113474.8A HK18113474A HK1254397A1 HK 1254397 A1 HK1254397 A1 HK 1254397A1 HK 18113474 A HK18113474 A HK 18113474A HK 1254397 A1 HK1254397 A1 HK 1254397A1
Authority
HK
Hong Kong
Prior art keywords
methods
cell therapy
cmv retinitis
treating cmv
treating
Prior art date
Application number
HK18113474.8A
Other languages
English (en)
Chinese (zh)
Inventor
理查‧约翰‧奥莱利
理查‧約翰‧奧萊利
苏珊‧伊莉莎白‧普罗科普
E‧道布罗维纳
蘇珊‧伊莉莎白‧普羅科普
冈瑟‧科伊内
艾莎‧纳斯林‧哈桑
E‧道布羅維納
西拉德‧基斯
岡瑟‧科伊內
艾莎‧納斯林‧哈桑
Original Assignee
纪念斯隆-凯特林癌症中心
紀念斯隆-凱特林癌症中心
康奈尔大学
康奈爾大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 纪念斯隆-凯特林癌症中心, 紀念斯隆-凱特林癌症中心, 康奈尔大学, 康奈爾大學 filed Critical 纪念斯隆-凯特林癌症中心
Publication of HK1254397A1 publication Critical patent/HK1254397A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/705—Specific hybridization probes for herpetoviridae, e.g. herpes simplex, varicella zoster
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
HK18113474.8A 2015-06-26 2016-06-21 通过t细胞疗法治疗cmv视网膜炎的方法 HK1254397A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562185558P 2015-06-26 2015-06-26
US62/185,558 2015-06-26
US201562191304P 2015-07-10 2015-07-10
US62/191,304 2015-07-10
PCT/US2016/038530 WO2016209816A1 (en) 2015-06-26 2016-06-21 Methods of treating cmv retinitis by t cell therapy

Publications (1)

Publication Number Publication Date
HK1254397A1 true HK1254397A1 (zh) 2019-07-19

Family

ID=56404300

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113474.8A HK1254397A1 (zh) 2015-06-26 2016-06-21 通过t细胞疗法治疗cmv视网膜炎的方法

Country Status (6)

Country Link
US (2) US10342864B2 (enExample)
EP (2) EP3756676B1 (enExample)
JP (1) JP2018518527A (enExample)
CN (1) CN107921065A (enExample)
HK (1) HK1254397A1 (enExample)
WO (1) WO2016209816A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
EP2812431B1 (en) 2012-02-09 2019-07-17 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
US11167024B2 (en) 2015-09-18 2021-11-09 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
EP3700553A1 (en) 2017-10-23 2020-09-02 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
EP3765602A1 (en) 2018-03-14 2021-01-20 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
CN113924331B (zh) * 2019-05-28 2024-09-13 东洋纺株式会社 聚酯薄膜、层叠薄膜及其用途
WO2021021937A1 (en) * 2019-07-29 2021-02-04 Baylor College Of Medicine Antigen-specific t cell banks and methods of making and using the same therapeutically
RU2740943C1 (ru) * 2020-03-23 2021-01-21 Борис Сергеевич Першин Способ лечения цитомегаловирусного ретинита после трансплантации гемопоэтических стволовых клеток

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595978A (en) * 1990-08-16 1997-01-21 Isis Pharmaceuticals, Inc. Composition and method for treatment of CMV retinites
ATE229810T1 (de) * 1996-10-11 2003-01-15 Univ California Krebs immuntherapie unter verwendung von tumorzellen kombiniert mit lymphozytmischungen
US6156317A (en) 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US6074645A (en) 1996-11-12 2000-06-13 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
US7041442B1 (en) 1999-06-04 2006-05-09 Florian Kern Peptides for vaccinating against human CMV
US6555675B2 (en) * 2000-08-21 2003-04-29 Inspire Pharmaceuticals, Inc. Dinucleoside polyphosphate compositions and their therapuetic use as purinergic receptor agonists
DE60109633T2 (de) 2000-10-20 2006-01-19 City Of Hope, Duarte Immunreaktive peptidische ctl-epitope aus dem menschlichen cytomegalovirus pp150
US7718196B2 (en) 2001-07-02 2010-05-18 The United States Of America, As Represented By The Department Of Health And Human Services Rapamycin-resistant T cells and therapeutic uses thereof
JP2005517637A (ja) * 2001-11-29 2005-06-16 セラコス・インコーポレイテッド 体外フォトフォレーシスおよび／またはアポプトーシス細胞による一定の被験体を前処理するための方法
EP1483575A2 (en) 2002-02-28 2004-12-08 Intercell AG Methods for isolating ligands e.g. t cell epitopes
US7163685B2 (en) * 2003-04-16 2007-01-16 City Of Hope Human cytomegalovirus antigens expressed in MVA and methods of use
CA2728739C (en) 2008-06-20 2017-07-11 Duke University Use of human cytomegalovirus antigens to enhance immune responses to cancer cells
MX2011005691A (es) 2008-11-28 2011-07-20 Univ Emory Metodos para el tratamiento de infecciones y tumores.
CA2772076A1 (en) 2009-08-24 2011-03-10 Baylor College Of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB0917094D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US20140303092A1 (en) * 2011-10-26 2014-10-09 Chimerix, Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
GB201121308D0 (en) * 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2017003763A1 (en) * 2015-06-27 2017-01-05 Memorial Sloan Kettering Cancer Center Methods of treating glioblastoma multiforme by t cell therapy

Also Published As

Publication number Publication date
EP3313419A1 (en) 2018-05-02
WO2016209816A1 (en) 2016-12-29
EP3313419B1 (en) 2020-08-19
US11103577B2 (en) 2021-08-31
CN107921065A (zh) 2018-04-17
EP3756676A1 (en) 2020-12-30
JP2018518527A (ja) 2018-07-12
US20200016261A1 (en) 2020-01-16
US20170128565A1 (en) 2017-05-11
US10342864B2 (en) 2019-07-09
EP3756676B1 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
SG11202105502RA (en) Methods for treatment using adoptive cell therapy
EP4403138A3 (en) Device and method with reduced pacemaker rate in heart valve replacement
MX2022015604A (es) Expresion transgenica selectiva de tejidos.
WO2016012544A3 (en) Enhanced reprogramming to ips cells
TW201612312A (en) Meristematic plant cells and method of isolating them
WO2015148863A3 (en) Crispr/cas-related methods and compositions for treating sickle cell disease
EP4591935A3 (en) Methods for the preparation of ribosides
EP3333130A4 (en) Water treatment system, power generation plant, and method for controlling water treatment system
WO2015138510A8 (en) Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
WO2015160806A3 (en) Improvements in transcutaneous energy transfer systems
IL250652A0 (en) Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss
EP3216859A4 (en) Differentiation-induced cell population from which undifferentiated cells have been removed, use of same, and method for producing same
GB201309758D0 (en) Generation of neural stem cells from human trophoblast stem cells
EP3229586A4 (en) Genetically modified cells, tissues, and organs for treating disease
WO2015168149A3 (en) Sensorineural hair cell differentiation
EP3342858A4 (en) ROR1-POSITIVE MESENCHYMAL STEM CELLS AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREOF, AND METHOD FOR PREVENTING OR TREATING DISEASES USING SAID ROR1 POSITIVE MESENCHYMAL STEM CELLS
WO2017048809A8 (en) Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
EP4545629A3 (en) Cell structure for brain damage treatment, production method thereof, and brain damage treatment agent
WO2017100782A8 (en) Systems and methods for optimized patient specific tissue engineering vascular grafts
EP3458572A4 (en) ENDOTHEL CELLS FROM HUMAN STEM CELLS, ENDOTHEL-HEPATOCYTE COCULTIVATION SYSTEM AND USES THEREOF
WO2014072982A3 (en) Tools and systems for solid form and graft implantation
WO2019118518A3 (en) Inducible cell receptors for cell-based therapeutics
IL291074A (en) Methods for preparing t cells for t cell therapy
WO2018146679A3 (en) Photoreceptor cells for the treatment of retinal diseases
EP3507601A4 (en) METHODS FOR THE IDENTIFICATION, TARGETING AND ISOLATION OF "PRE-DC" HUMAN DENDRITIC CELL (DC) PRECURSORS, AND USES OF THESE LATEST